Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ADMA Biologics (ADMA)

ADMA Biologics Q3 revenue rises 78% to $119.8 million; raises 2024 and 2025 guidance

Positive Impact 4 of 5 earnings Written later

ADMA Biologics reported third quarter 2024 revenue of $119.8 million, up 78% from a year earlier, and GAAP net income of $35.9 million, compared with $2.6 million in the prior-year quarter. The company raised its full-year 2024 and 2025 revenue, GAAP net income and Adjusted EBITDA guidance, and appointed KPMG LLP as its new independent auditor.

Key points

  • Q3 2024 revenue was $119.8 million versus $67.3 million in Q3 2023; corporate gross margin was 50% versus 37%.
  • Q3 2024 GAAP net income was $35.9 million, or $0.15 per diluted share, versus $2.6 million a year earlier.
  • FY 2024 revenue guidance rose to more than $415 million from more than $400 million; FY 2024 GAAP net income guidance rose to more than $120 million from $105 million.
  • KPMG LLP was engaged as the new independent registered public accounting firm effective November 7, 2024, succeeding CohnReznick.

The filing

CompanyADMA Biologics (ADMA)
Form8-K, current report
Filed with the SECNov 7, 2024, 4:10 PM ET
Accession number0001140361-24-045657

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 07, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.